Circulating nucleic acids as a tumor marker

Histology and Histopathology

Volumn 17, Issue 3, 2002, Pages 937-943

  Chan, K C A ^a   Lo, Y M Dennis ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; Circulating nucleic acids; Plasma serum DNA; Tumor markers

Indexed keywords

MITOCHONDRIAL DNA; NUCLEIC ACID; TUMOR MARKER;

BLOOD LEVEL; CANCER; CANCER GROWTH; CANCER SCREENING; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; GENE MUTATION; GENETIC DISORDER; HUMAN; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; NUCLEIC ACID ANALYSIS; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; ONCOGENE; OUTCOMES RESEARCH; PATIENT MONITORING; PREDICTION; PROGNOSIS; REVIEW; VIRUS INFECTION;

DNA, MITOCHONDRIAL; DNA, NEOPLASM; HUMANS; MICROSATELLITE REPEATS; MUTATION; NEOPLASMS; NUCLEIC ACIDS; PLASMA; RNA; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 0036062060     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
2. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics
3. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma
4. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: Diagnostic utility and prognostic significance
5. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer
6. Telomerase RNA as a detection marker in the serum of breast cancer patients
7. Microsatellite alterations in plasma DNA of small cell lung cancer patients
8. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients
9. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma
10. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis
11. Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: A simple blood test to monitor disease in cancer patients
12. Detection of tumour DNA in serum of colorectal cancer patients
13. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome
14. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia
15. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
16. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
17. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients
18. Cell-tree DNA in human blood plasma: Length measurements in patients with pancreatic cancer and healthy controls
19. p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas
20. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance
21. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
22. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
23. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B
24. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
25. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
26. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
27. Molecular detection of genetic alterations in the serum of colorectal cancer patients
28. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma
29. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells
30. Mitochondrial mutations in early stage prostate cancer and bodily fluids
31. Herpermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma
32. Circulating RNA as a tumor marker: Detection of 5T4 mRNA in breast and lung cancer patient serum
33. Detection of tumor messenger RNA in the serum of patients with malignant melanoma
34. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer
35. Free DNA in the serum of cancer patients and the effect of therapy
36. Nasopharyngeal carcinoma: The Epstein-Barr virus association
37. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma
38. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA
39. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma
40. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma
41. Kinetiocs of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma
42. Les acides nucleiques du plasma sanguin chez l'homme
43. Mutations of p53 gene can be detected in the plasma of patients with large bowel carcinoma
44. Checkpoint genes in cancer
45. Mutations of Kiras and p53 genes in colorectal cancer and their prognostic significance
46. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients
47. Microsatellite alterations in serum DNA of head and neck cancer patients
48. Circulating tumor-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas
49. Mitochondrial DNA in human malignancy
50. Human papillomavirus DNA in plasma of patients with cervical cancer
51. Elevated serum ribonuclease in patients with pancreatic cancer
52. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients
53. p53 mutation in plasma DNA and its prognostic value in breast cancer patients
54. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer
55. Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations
56. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics
57. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients
58. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients
59. A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer
60. Soluble normal and mutated DNA sequences from single-copy genes in human blood
61. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients
62. Neoplastic characteristics of the DNA found in the plasma of cancer patients
63. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients
64. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia
65. A structure for deoxyribose nucleic acid
66. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients
67. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications
68. Relationship of P16 methylation status and serum alpha-fetoprotein concentration in hepatocellular carcinoma patients
69. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients
70. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: Correlation with clinicopathological features